First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).
复制标题
DOI：
10.1200/jco.2020.38.15_suppl.3500
复制
发表时间：
2020-05
影响因子：
45.3
通讯作者：
D. Petrylak;Xin Gao;N. Vogelzang;Mary Garfield;I. Taylor;Marcia Dougan Moore;R. Peck;H. Burris
中科院分区：
文献类型：
--
作者：
D. Petrylak;Xin Gao;N. Vogelzang;Mary Garfield;I. Taylor;Marcia Dougan Moore;R. Peck;H. Burris
3500背景：蛋白水解靶向嵌合体 (PROTAC) 蛋白降解剂通过与泛素蛋白酶体系统结合诱导目标蛋白的选择性降解。 ARV-110 是一种口服生物药...
3500Background: Proteolysis Targeting Chimera (PROTAC) protein degraders induce selective degradation of targeted proteins by engaging the ubiquitin proteasome system. ARV-110 is an orally bioavail...